600873 梅花生物
2026/03 - 三个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入5,985,632-4.51%24,208,67525,069,28827,760,61227,937,153
减:营业总成本5,882,48212.80%21,603,82121,862,60024,158,62322,990,081
    其中:营业成本5,415,27714.57%19,609,39920,036,69922,297,12220,915,784
               财务费用25,546-221.48%4,005(117,264)(33,427)83,877
               资产减值损失66-136.52%(36,035)(6,982)(5,415)(5,958)
公允价值变动收益3,922-58.04%32,83814,826(38,116)32,687
投资收益11,987-12.05%57,84830,1937,62724,365
    其中:对联营企业和合营企业的投资收益(661)-369.85%(2,117)(3,018)1,8463,074
营业利润139,274-88.45%2,909,0623,491,2853,813,3935,160,179
利润总额154,317-87.16%3,729,7003,349,4613,723,1365,152,795
减:所得税费用36,396-80.17%448,820609,033542,186746,553
净利润117,921-88.42%3,280,8802,740,4273,180,9504,406,242
减:非控股权益------------
股东净利润117,921-88.42%3,280,8802,740,4273,180,9504,406,242

市场价值指针
每股收益 (元) *0.040-88.89%1.1700.9401.0601.440
每股派息 (元) *----0.4280.6020.4200.400
每股净资产 (元) *5.8548.09%5.8305.1094.8124.442
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容